Home

Applications

APPLICATIONS OVERVIEW
DRUG DISCOVERY
ADME-Tox
Biochemical Assays
Cell-based Assays
HTS and Secondary Screening
Microsampling
Protein Crystallography
RNAi
Sample Management
CANCER RESEARCH
Personalized Medicine
Functional Screening / DSRT
RNAi
Sequencing
Single-cell Genomics
GENOMIC RESEARCH
Gene Expression
Genotyping
Microbiome
qPCR
Sequencing
Single-cell Genomics
Synthetic Biology

Products

LIQUID HANDLING
LIQUID HANDLERS OVERVIEW
Echo® 525 Liquid Handler
Echo® 555 Liquid Handler
Echo® 550 Liquid Handler
Echo® 520 Liquid Handler
AUTOMATION
AUTOMATION OVERVIEW
Access™ Laboratory Workstation
Tempo™ Automation Control Software
SOFTWARE APPLICATIONS
SOFTWARE OVERVIEW
Echo® Array Maker
Echo® Cherry Pick
Echo® Combination Screen
Echo® Compliance Manager
Echo® Dose-Response
Echo® Plate Audit
Echo® Plate Reformat
CONSUMABLES
CONSUMABLES OVERVIEW
Echo® Qualified Microplates
Labcyte® Assay Microplates
MicroClime® Environmental Lid
Echo® Qualified Reservoir

Technology

Echo® Acoustic Liquid Handling
Dynamic Fluid Analysis™
Acoustic Mass Spectrometry
Direct Dilution

News / Events

Labcyte BLOG
Upcoming Events
Press Releases
Labcyte in the News
Labcyte Community

Resources

JALA Special Issue
Publications
Articles and Other Media
Application Notes
Posters
Webinars
Videos
Customer Profiles
Core Labs

Support

Brochures
Web Documentation*
User Guides*
Quick Start Guides*
Specification Sheets
Site Prep Guides
Service and Maintenance
Request Information

Company

About Us
Echo® Acoustic Technology
Leadership Team
Meet Labcyte
Careers
Contact and Location
Privacy Policy

GSK, AstraZeneca and Labcyte Form Alliance to Develop Acoustic Mass Spectrometry

a Novel Sample Handling Technology for MS-based Drug Discovery

September 20, 2017

SAN JOSE, CA

Labcyte Inc. today announced that GSK has joined its consortium with AstraZeneca to combine acoustic liquid dispensing technology from Labcyte with Mass Spectrometry (MS) for use in high throughput small molecule screening and other drug discovery applications. Acoustic liquid dispensing, pioneered by Labcyte, uses the gentle energy of sound waves to move minute quantities of liquid with precision and accuracy. It has been enhanced to generate an MS-friendly mist of nano-droplets in a process called Acoustic Mist Ionization (AMI). Mass spectrometers are currently used to quantify the amount of drug substance present in screening assays, drug metabolism studies, and safety and efficacy experiments. The use of MS through AMI in high throughput applications has the potential to reduce both cost and cycle time in early drug discovery.


“Labcyte’s standard acoustic liquid handling has already been deployed across many areas of life science research and drug development as the result of its many benefits,” said Mark Fischer-Colbrie, Chief Executive Officer at Labcyte. “Our goal is to continue that expansion with Acoustic-MS. We have made significant progress in collaboration with AstraZeneca over the past four years with great results. This new consortium will help validate new applications and optimize the Acoustic-MS technology for both creating new workflows as well as for fitting into existing drug discovery processes.”


With the addition of GSK, the companies have formed a consortium to advance the development of Acoustic-MS for high-throughput chemistry analysis, and biochemical and cell-based assays supporting a range of drug targets. Both pharmaceutical companies will work with multiple prototype instruments – applying the technology to high-priority assays – and will share their findings with other members of the consortium. Labcyte plans to launch a commercial Acoustic-MS system designed to support a broad range of assays.


AstraZeneca has demonstrated the technology’s significant capabilities to conduct biochemical screening applications at rates up to three samples per second. For example, AZ recently completed a full library screen of 2.7 million compounds in less than six weeks using this approach. AstraZeneca’s Jonathan Wingfield, Principal Scientist, Discovery Sciences, Innovative Medicines AZ, is excited about these great advancements. “We have proven that Acoustic-MS technology works, and generates vastly reduced assay development times, improved cost savings and fewer false positives. The addition of GSK provides the opportunity to expand the development of this technology and reinforces AstraZeneca’s commitment to open innovation.”


Melanie Leveridge, Director, Screening, Profiling and Mechanistic Biology at GSK, commented: “We value innovation and collaborative development, and are excited to be working with Labcyte and AstraZeneca to further develop Acoustic-MS for high throughput screening applications, as well as exploring new opportunities for this technology in high throughput chemistry analysis.”



About Labcyte Inc.

Labcyte, a global biotechnology tools company headquartered in San Jose, California, is revolutionizing liquid handling. Echo® liquid handling systems uses sound to precisely transfer liquids without contact, eliminating the use of pipettes. Labcyte instruments are used worldwide throughout the pharmaceutical and biotechnology industries, as well as by hospitals, service laboratories, contract research organizations, and academic institutions. Our customers work across a wide spectrum of scientific research, including drug discovery, genomics, proteomics, diagnostics and personalized medicine. Labcyte has 60 U.S. patents and others internationally. For more information, visit www.labcyte.com.



PR Contact:
Nicole Litchfield
Bioscribe, Inc.
415-793-6468
nicole@bioscribe.com





MAIN CONTACT
LABCYTE INC.
170 Rose Orchard Way
San Jose, California 95134
USA
Tel:
+1 408 747-2000
Toll-free:
+1 877 742-6548
Sales:
+1 877 742-6548, option 1
Fax:
+1 408 747-2010
Contact:
REQUEST INFO

PRESS CONTACT
Nicole Litchfield
Bioscribe, Inc.
Tel:
+1 415 793-6468
Email:
nicole@bioscribe.com
TOP